Primary results from a phase 2a study of zanidatamab (zani) plus palbociclib (palbo) plus fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)

被引：1
|
作者：
Escriva-de-Romani, Santiago
Cejalvo, Juan Miguel
Alba, Emilio
Friedmann, Jennifer
Lescure, Alvaro Rodriguez
Savard, Marie-France
Pezo, Rossanna C.
Gion, Maria
-Borrego, Manuel Ruiz
Hamilton, Erika
Pluard, Timothy
Webster, Marc
Beeram, Muralidhar
Linden, Hannah
Saura, Cristina
Shpektor, Diana
Salim, Bob
Harvey, Phoebe
Hurvitz, Sara
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-LBO1-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBO1-04
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study
    Welt, A.
    Welslau, M. K.
    Lueftner, D.
    Deryal, M.
    Liersch, R.
    Sahlmann, J.
    Houet, L.
    Vannier, C.
    Marschner, N.
    Potthoff, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Frontline Fulvestrant, Palbociclib Combo Is Effective for Endocrine-Sensitive, HR+/HER2-Metastatic Breast Cancer
    不详
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 486 - 486
  • [23] Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2-Metastatic Breast Cancer
    Jeselsohn, Rinath
    Fu, Jingxin
    Ren, Yue
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy
    Abdou, Yara
    Riley, Elizabeth
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Ko, Naomi
    Liu, Yuan
    Burstein, Harold
    DeMeo, Michelle
    Tolaney, Sara
    Mayer, Erica
    CANCER RESEARCH, 2024, 84 (09)
  • [24] Palbociclib Plus Fulvestrant as Second- or Later-Line Therapy for Patients with Locally Advanced, Inoperable or Metastatic HR+/HER2-Breast Cancer in Germany: Interim Results of the Inge-B Phase 2 Study
    Lueftner, Diana
    Welslau, Manfred
    Liersch, Ruediger
    Deryal, Mustafa
    Brucker, Cosima
    Rauh, Jaqueline
    Welt, Anja
    Zaiss, Matthias
    Sahlrnann, Joerg
    Houet, Leonora
    Vannier, Corinne
    Potthoff, Karin
    Marschner, Norbert
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 14 - 14
  • [25] registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Tripathy, D.
    Kaufman, P.
    Brufsky, A.
    Mayer, M.
    Yood, M.
    Wang, L.
    Brammer, M.
    Yardley, D.
    Tan-Chiu, E.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer
    Sledge, G. W.
    Toi, M.
    Neven, P.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Kaufman, P. A.
    Koh, H.
    Grischke, E-M.
    Conte, P. F.
    Lu, Y.
    Barriga, S.
    Hurt, K.
    Frenzel, M.
    Johnston, S. R. D.
    Llombart-Cussac, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 856 - 856
  • [27] Post progression treatments after endocrine therapy (ET) plus palbociclib in patients with HR+/HER2-metastatic breast cancer (MBC): A prospective, real-world study
    Palumbo, R.
    Saltalamacchia, G.
    Quaquarini, E.
    Tagliaferri, B.
    Teragni, C. M.
    Barletta, C.
    Frascaroli, M.
    Biscaldi, E.
    Malovini, A.
    Locati, L. D.
    Sottotetti, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S372 - S372
  • [28] Biomarker analysis from a phase I study using gedatolisib plus palbociclib plus hormone therapy in ER+/HER2-metastatic breast cancer (mBC).
    Wesolowski, Robert
    Pathan, Nuzhat
    Zhu, Zhou
    Stringer-Reasor, Erica Michelle
    Han, Hyo S.
    Dees, Elizabeth Claire
    Bardia, Aditya
    Layman, Rachel M.
    Weise, Amy
    Kabos, Peter
    Lu, Janice M.
    Kern, Kenneth Alan
    Pierce, Kristen J.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T plus AI vs L plus AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.
    Gradishar, William John
    Hegg, Roberto
    Im, Seock-Ah
    Park, In Hae
    Tjulandin, Sergei
    Kenny, Sarah
    Sarp, Severine
    Williams, Lisa
    Izquierdo, Miguel A.
    Johnston, Stephen R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2-patients with metastatic breast cancer
    Li, Jingping
    Zhang, Xiangmei
    Yang, Chao
    Lv, Yalei
    Yang, Hua
    Kong, Xiangshun
    Han, Meng
    Wang, Zunyi
    Ma, Jie
    Han, Jianjun
    Liu, Yunjiang
    MEDICINE, 2021, 100 (44)
12345